Mr. Zezhou Wang reports
TRILLIUM THERAPEUTICS TO UNVEIL ITS STING AGONIST PROGRAM AT THE AACR ANNUAL MEETING 2019
Trillium Therapeutics Inc. will be presenting preclinical data from its previously undisclosed STING agonist program at the annual meeting of the American Association for Cancer Research. The meeting will be held March 29 to April 3 in Atlanta, Ga. Details of the poster presentation are listed below.
Title: "Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice"
Presenter: Zezhou Wang, PhD, Trillium Therapeutics
Date and time: April 2, 2019, from 1 p.m. to 5 p.m. ET
Location: Georgia World Conference Center, Poster Section 12
Abstract No.: 3854
About Trillium Therapeutics Inc.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.
© 2020 Canjex Publishing Ltd. All rights reserved.